Showing posts with label open access journal of Gastroenterology and Hepatology. Show all posts
Showing posts with label open access journal of Gastroenterology and Hepatology. Show all posts

Tuesday, 30 November 2021

Lupine Publishers| Chemically-Induced Peptic Ulcer: Gastroprotective Effects of Peach Fruit

 Lupine Publishers| Journal of Gastroenterology and Hepatology



Abstract

Background: Peptic ulcer, an inflammatory breach in the gastric and duodenal mucosa, is caused by hyper secretion of gastric acid and defective mucosal protective elements, affecting approximately 4 million people each year. The currently available antiulcer drugs are reported to have severe side effects. Hence, there is a need to develop more effective and less toxic alternative therapeutic agents from natural sources. The current study was conducted to investigate the therapeutic potential of Prunus persica Linn. Batsch fruit (Peach) against chemically-induced gastric and duodenal ulcers.

Material and Methodology: 70% aqueous methanolic crude extract of Prunus persica (Pp.Cr) was prepared. Gastroprotective effects were evaluated by oral administration of Pp.Cr at the doses of 100, 300, 500 mg/kg for ten days. Normal control and intoxicated groups were treated with distilled water. Bismuth subsalicylate (88 mg/kg) was administered to the standard control group. On 10th day, all animals were intoxicated with ethanol (5 ml/kg) except normal control group, and one hour after intoxication, all animals were sacrificed, stomach isolated; and pH and acidity of gastric contents, ulcer index and percentage protection were calculated. One stomach from each group was analyzed histo pathologically. Duodenal protective effects were assessed by administering Pp.Cr (100, 300, 500 mg/kg) for fourteen days. The standard control group was treated with cimetidine (100 mg/kg). On 14th day, cysteamine (600 mg/kg) was administered in two divided doses at an interval of four hours to experimental animals to induce duodenal ulcer. All animals were dissected out 48 hours after the administration of first dose of cysteamine. Duodenum was isolated and analyzed for severity score. Histopathological examination of one duodenum from each group was performed.

Results: In gastric ulcer model, Pp.Cr was found to increase pH and decrease the total acidity of gastric contents, and decrease the ulcer index, in dose-dependent manner at the doses of 100, 300 and 500 mg/kg. In duodenal ulcer model, Pp.Cr was observed to decrease the severity score and ulcer index, again in dose-dependent manner.

Conclusion: The results of current study demonstrate the gastric and duodenal protective effects of the crude extract of Prunus persica (Pp.Cr), corroborating their folkloric use in the prevention and treatment of peptic ulcer.

Keywords: Ulcer; Duodenum; Prunus persica; Gastroprotective; Gastric Ph; Ulcer Index

Introduction

Peptic ulcer, an inflammatory breach in the lining of GIT, results from hyper secretion of gastric acid or defects in mucosal protective factors [1]. The most frequent sites of ulcer formation are stomach and proximal portion of duodenum and the ratio of duodenal to gastric ulcers is 4:1 [2]. Peptic ulcer is caused by various noxious factors; such as Helicobacter pylori infection, NSAIDs, alcohol intake, smoking and stress. 60% of gastric and up to 90% of duodenal ulcers develop due to the H. pylori infection [3]. Peptic ulcer can be treated through different approaches, based on chemically synthesized drugs; i.e. reduction of gastric acid secretion (proton pump inhibitors, H2 receptors antagonists, anticholinergics, prostaglandin analogues), neutralization of gastric acid secretion (antacids), protection of GIT mucosa (sucralfate, bismuth subsalicylate) and use of antimicrobial drugs like amoxicillin, clarithromycin, tetracycline and metronidazole [4]. No doubt, the available drugs have reduced the incidence and prevalence of peptic ulcer but they are associated with severe side effects; such as impotence, arrhythmias, hyperplasia, gynaecomastia, and hematopoietic changes [5]. Therefore, there is a constant need to explore the new possible therapies with lesser side effects to reduce or treat the peptic ulcer problems and plants are the best alternatives which are being used from the ancient times. World Health Organization (WHO) has estimated that about 75% of the world’s population rely on herbal medicines for the prevention and treatment of various diseases because of their fewer side effects and low cost. Approx. 80% of population in Pakistan is using indigenous plants for the treatment of various diseases [6]. Prunus persica used in the present study is a tree or large shrub having tremendous medicinal importance.

Different parts of plant; i.e. leaves, flowers, fruits, kernels of fruit and seeds have traditional medicinal uses and extensively studied. The plant is used for the treatment of whooping cough, chronic bronchitis and gastritis. The plant has demulcent, antiscorbutic, aphrodisiac, anti-pyretic and anthelmintic activities. Leaves have demulcent, expectorant, vermicidal, anthelmintic, insecticidal, sedative and diuretic properties. Leaf paste is used externally to kill worms in wounds and fungal infections. The flowers are used as laxative and diuretic, oil extracted from seeds, is used for the treatment of piles, stomach troubles of children and earache and used as an abortifacient. Peach kernels are used for the treatment of menstrual disorders, blood disorders, coughs and rheumatism. The bark is used to treat the leprosy and jaundice [7]. Prunus persica has been reported to possess Antiallergic [8], Antibacterial [9], Anti-inflammatory [10], Antiphotoaging [11], Prokinetic [12] and Antioxidant properties [13]. Hence, indigenous medicinal plant; Prunus persica, was selected on the basis of its traditional use as antiulcer agent. The objective of the current study was to investigate the antiulcerogenic potential of the crude extract of Prunus persica fruit by using chemically-induced peptic ulcer models; i.e. ethanol induced-gastric ulceration and cysteamineinduced duodenal ulceration.

Research Methodology

Material and Equipment

All chemicals used in experiments were of analytical grade including; Bismuth subsalicylate, Cimetidine, Cysteamine hydrochloride, Ethanol, Formalin, Ketamine and Xylazine. Equipment used were centrifuge machine, digital weighing balance, oven, pH meter, refrigerator, rotary evaporator and vortex mixer.

Phytochemical Section

Collection of Plant Material: The frsesh fruit of Prunus persica (Peach) was purchased from local market of Bahawalpur, Pakistan. After collection, plant was identified by authentic botanist; Mr. Abdul Hamid, department of Life Sciences, the Islamia University of Bahawalpur, Pakistan. Dried plant specimen was deposited in Herbarium of Pharmacology research laboratory, department of Pharmacy and Alternative Medicine, the Islamia University of Bahawalpur, Pakistan. Voucher number PP-FT-05-15-92 was issued for future reference.

Preparation of the Crude Extract: After removal of seeds, fresh fruit of Prunus persica was cut into small pieces and soaked in 70 % aqueous methanol for three days with occasional shaking at room temperature. Then the soaked material was filtered first through muslin cloth and then through filter paper. The process of soaking and filtration was repeated twice. After third filtration, residue was discarded. Filtrate was subjected to evaporation using rotary evaporator to remove solvent under reduced temperature (50°C) and pressure. The obtained crude extract was then labelled as Pp.Cr and weighed to calculate percentage yield. The extract was stored in freezer for future use.

Phytochemical Analysis of Pp.Cr: The crude extract of Prunus persica (Pp.Cr) was subjected to phytochemical analysis for the detection of secondary metabolites; i.e. alkaloids, carbohydrates, coumarins, flavonoids, glycosides, phenols, phlobatannins, proteins, quinones, saponins, tannins and terpenes.

Pharmacological Section

Experimental Animals: Wistar albino rats (150-250 g) and Swiss albino mice (18-30 g) of either sex were housed in animal house of Pharmacology Research Laboratory, department of Pharmacy, faculty of Pharmacy and Alternative Medicine, the Islamia University of Bahawalpur. Animals were kept in polycarbonate cages (47×34×18 cm3) under standard conditions of temperature (25±2°C), humidity (60±5 %) and 12 h/12 h light and dark cycle. Animals were provided with standard pellet diet and tap water ad libitum and allowed to acclimatize for at least one week before the commencement of experiment. The study protocols and procedures were approved by the Institutional Research Ethics Committee of department of Pharmacy and Alternative Medicine, Islamia University of Bahawalpur; i.e. Pharmacy Research Ethics Committee (PREC) and the reference No. 40-2015/PREC; dated 02.09.2015 was issued for future reference.

Experimental Models: Peptic ulcer was induced by intragastric administration of ethanol (gastric ulcer) and cysteamine hydrochloride (duodenal ulcer) to evaluate the antiulcer potential of Pp.Cr.

a) Ethanol-Induced Gastric Ulcer: Gastric ulcer was induced by oral administration of ethanol (5ml/kg) in wistar albino rats, according to the method described by Ahmed [14]. Animals were divided into six groups, each comprises of six animals. Normal control group and intoxicated groups were treated with distilled water (5 ml/kg, p.o) for 10 days. Treatment groups received different doses (100, 300 and 500 mg/kg) of Pp.Cr and the standard control group was treated with bismuth subsalicylate (88 mg/ kg) for 10 days. On 10th day, one hour after respective treatment to 24 hour fasted rats, ethanol (5 ml/kg) was administered orally to all the animals except the normal control group. One hour after administration of ethanol, all animals were anaesthetized with ketamine (50 mg/kg)/Xylazine (5 mg/kg) combination and sacrificed. The stomach was isolated from each animal and gastric contents were collected in centrifuge tubes.

i) Analysis of Gastric Contents for Ph and Total Acidity

Gastric contents were centrifuged at 1000 rpm for 10 minutes. pH of supernatant was noted using pH meter. 1ml of supernatant liquid was taken in conical flask and diluted with distilled water to make the volume up to 10 ml. Two or three drops of phenolphthalein were added in this solution and titrated with 0.01N NaOH until the appearance of pink colour. The volume of 0.01N NaOH used corresponds to total acidity which is expressed as mEq/L/100g of gastric contents. Total acidity was calculated using following formula: Acidity (meq/L/100g) = (Vol. of NaOH × Normality × 100)/0.1

ii) Scoring of Ulcer

0 = No ulcers

1 = Changes on superficial layer of the mucosa without congestion

2 = Necrotic changes on half the mucosal thickness

3 = Necrotic changes on more than 2/3rd of the mucosal thickness

4 = Complete mucosal destruction with hemorrhage

iii) Determination of Ulcer Index and % Protection

The Ulcer Index (UI) was calculated using following formula:

UI = Un + Us + Up × 10−1

Un = average number of ulcers per animal

Us = average severity score

Up = percentage of animals with ulcers

% Protection was calculated using following formula:

% Protection= UI Intoxicated-UI treated/UI Intoxicated × 100 [16].

b) Cysteamine-Induced Duodenal Ulcer: Duodenal ulcer was induced by oral administration of cysteamine hydrochloride (600 mg/kg) in two divided doses at an interval of 4 hours in wistar albino rats, according to the method described by Santos with slight modifications [17]. Animals were divided into six group, each comprising of six animals. Normal control and intoxicated groups were treated with distilled water (5ml/kg) for 14 days. Treatment groups received different doses (100, 300 and 500mg/kg) of Pp.Cr, the standard control group was treated with cimetidine (100 mg/ kg) for 14 days. On 14th day, one hour after respective treatment, cysteamine hydrochloride (600 mg/kg) was administered orally in two doses at an interval of 4 hours to all animals except the normal control group. Twenty four hours fasted animals were dissected out 48 hours after the first dose of cysteamine hydrochloride. Duodenum from each animal was isolated and analyzed for severity score.

i) Scoring of Ulcer: Duodenum from each animal was cut open along the antimesenteric side and washed with normal saline. Ulcer scoring was done according to severity of ulcer with the help of magnifying glass.

0 = No ulcer

1 = Superficial lesions on duodenal muco

2 = Deep ulcer or transmural ulcer

3 = Perforated or penetrated ulcer

ii) Determination of Ulcer Index and % Protection: The Ulcer Index (UI) was calculated using following formula:

UI= Average of severity score + (ratio of ulcer positive/total animal in each group × 2)

% Protection was calculated using following formula:

% Protection= UI intoxicated-UI treated/ UI intoxicated × 100 [18]

c) Histopathological Examination

The isolated stomach and duodenum were preserved in 10% formalin. Tissues were sectioned at 5 μm, stained with Haematoxylin and Eosin and analyzed under light microscope to observe histopathological changes; e.g. oedema, inflammation, infiltration and erosion in stomach and duodenum [13].

d) Acute Toxicity Test

Acute toxicity assay was performed according to the guidelines of OECD (Organization of Economic Co-operation and Development). Swiss albino mice weighing 18-30g were divided into 5 groups each consisting of 5 animals. Mice were fasted overnight before the study, however food was provided to the animals during the study. Normal control group received distilled water (10 ml/kg) orally whereas treatment groups received different doses; i.e. 500, 1000, 5000 and 10,000 mg/kg of Pp.Cr. Following parameters were observed: alertness, grooming, writhing reflex, corneal reflex, convulsions, lacrimation, salivation, urination, sweating, hyperactivity, touch response, pain response, gripping strength and righting reflex at 0.5, 1, 2, 4, 6, 12, 24, 48, 72 hours, 7 and 14th day and mortality, if any, was noted after 48 hours [19].

Statistical Analysis

The interpretation of the results was done by expressing the data as Mean + SEM. Results of treatment groups were compared with intoxicated group using one way Analysis of Variance (ANOVA). All the data was analyzed using Graph Pad Prism software version 5. The results were considered to be significant at p < 0.05 level.

Results

Phytochemical Analysis

Medicinal plants are backbone of traditional system of medicine and are enriched in phytochemical constituents which serve as lead compounds in drug discovery and design. In the current study, 70% aqueous methanolic extract of Prunus persica (Pp.Cr) was prepared and phytochemical analysis was performed that confirms the presence of alkaloids, carbohydrates, flavonoids, glycosides, phenols, proteins, tannins and terpenes.

Pharmacological Section

Acute Toxicity Studies

It was observed that the 70% methanolic crude extract of the plant P. persica was safe up to the dose of 10 g/kg.

Gastroprotective Effects of Pp.Cr against Ethanol-Induced Gastric Ulceration

a) Effects of Pp.Cr on Ph of Gastric Contents

It was observed that Intoxicated group showed highly significant (p<0.001) reduction in pH of gastric contents as compared to normal control group. The pH of gastric contents in bismuth subsalicylate treated group was highest which was statistically highly significant (p<0.001) when compared with the intoxicated group. Pretreatment with 100, 300 and 500 mg/ kg of Pp.Cr produced highly significant (p<0.001) increase in pH dose dependently (as shown in Figure 1A) in comparison with intoxicated group. The effects of Pp.Cr are summarized in Table 1.

Figure 1: The graphs showing the effects of the crude extract of Prunus persica (Pp.Cr) alongwith bismuth subsalicylate (BSS), on (A) pH of gastric contents, (B) Acidity, (C) Ulcer index and (D) percent gastric protection in ethanol-induced gastric ulceration in rats.

lupinepublishers-openaccess-journal-gastroenterology-hepatology

Table 1: The effects of the crude extract of Prunus persica (Pp.Cr) alongwith bismuth subsalicylate, on pH, total acidity of gastric contents, ulcer index and % protection in ethanol-induced gastric ulceration in rats.

lupinepublishers-openaccess-journal-gastroenterology-hepatology

The values are expressed as mean ± SEM of six animals in each group and the results are analyzed using one way ANOVA. The values of treated groups are compared with those of intoxicated group. P values are considered as significant (*) if p<0.05 and highly significant (***) if p<0.001. The values of intoxicated group are also compared with normal control group and considered highly significant (###) if p<0.001.

b) Effects Pp.Cr on Total Acidity of Gastric Contents

Oral administration of the crude extract of Prunus persica (Pp. Cr), at the doses of 100, 300 and 500 mg/kg, as well as bismuth subsalicylate (88 mg/kg) for ten days showed the dose-dependent reduction in total acidity of gastric contents (Table 1). The rise in total acidity in intoxicated group was highly significant (p<0.001) as compared to normal control group. BSS treated group exhibited significant (p<0.001) reduction in total acidity as compared to the intoxicated group. Pp.Cr 100 mg/kg significantly (p<0.05) reduced the total acidity when compared with intoxicated group. The total acidity values for Pp.Cr treated groups at the doses of 300 mg/kg and 500 mg/kg showed highly significant reduction in total acidity as compared to intoxicated group; i.e. P<0.001 as depicted in Figure 1B. The results Pp.Cr (500 mg/kg) were comparable with BSS treated group.

c) Effects of Pp.Cr on Ulcer Index

The crude extract of Prunus persica (Pp.Cr) was observed to decrease the ulcer index in dose- dependent fashion as summarized in Table 1. The value of ulcer index in intoxicated group was 11.21 while it was 3.3 in BSS treated group. The values of ulcer indices in Pp.Cr treated groups were found to be; 8.93, 6.20 and 4.95 at the doses of 100, 300 and 500 mg/kg respectively. The results are elaborated in Figure 1C.

d) Effects of Pp.Cr on Gastric Percent Protection

The percentage protection shown by Pp.Cr after 10 days of the administration was 20.33%, 44.69%, and 55.84% at the doses of 100, 300 and 500 mg/kg as shown in Table 1. The gastric percent protection at different doses of Pp.Cr that is dose-dependent (Figure 1D). The standard control group showed the highest gastroprotective effects; i.e. 70.56%.

Figure 2: The effects of different doses of Pp.Cr and bismuth subsalicylate on ethanol-induced histopathogical alterations (A) normal control, (B) intoxicated (ethanol 5 ml/kg), (C) Pp.Cr 100 mg/kg + intoxication, (D) Pp.Cr 300 mg/kg + intoxication, (E) Pp.Cr 500 mg/kg + intoxication and (F) BSS 88 mg/kg + intoxication

lupinepublishers-openaccess-journal-gastroenterology-hepatology

Histopathological examination of stomach from one animal of each group was performed to confirm the ulcer formation and to evaluate the gastroptrotective effects of different doses of Pp.Cr. No gastric mucosal damage was observed in normal control group (Figure 2A). Intoxicated group showed the typical characteristics of ethanol-induced ulcer; i.e. gastric mucosal damage, edema and leucocytes infiltration of the mucosal layer (Figure 2B). Histological examination indicated that pretreatment with different doses 100, 300 and 500 mg/kg (Figures 2C-2E) of Pp.Cr and bismuth subsalicylate (88 mg/kg, Figure 2F) showed the gastroprotective effects as evidenced by reduction in mucosal damage and edema. Pp.Cr was found to prevent the mucosal damage significantly

Protective Effects of Pp.Cr against Cysteamine-Induced Duodenal Ulceration

Effects of Pp.Cr on Severity Score of Duodenal Ulcer

Table 2: The effects of the crude extract of Prunus persica (Pp.Cr) along with cimetidine on severity score, ulcer index and duodenal percent protection in cysteamine-induced duodenal ulceration in rats.

lupinepublishers-openaccess-journal-gastroenterology-hepatology

The values are expressed as mean ± SEM of six animals in each group and the results are analyzed using one way ANOVA. The values of treated groups are compared with those of intoxicated group. P-values are considered as significant (*) if p<0.05, more significant (**) if p <0.01 and highly significant (***) if p<0.001.

The effects of Pp.Cr on severity index of duodenal ulcer are tabulated in Table 2. The mean value of severity score in intoxicated group, treated with cysteamine, was calculated as 2.5±0.22. Cimetidine (100 mg/kg), an antisecretory agent, selected as the standard drug for the study, showed highly significant (p<0.001) reduction in severity score when compared with intoxicated group. The effects of Pp.Cr (100 mg/kg) on severity score were insignificant (P>0.05) when compared with intoxicated group. Pp.Cr (300 mg/kg) was able to reduce severity score significantly (p<0.05) as compared with intoxicated group. Pp.Cr (500 mg/kg) showed more significant (p<0.01) reduction in severity score as shown in Figure 3A.

Effects of Pp.Cr on ulcer index

Cysteamine produced the inflammatory changes and hemorrhagic spots in duodenum. No duodenal mucosal damage was observed in normal control group. The crude extract of Prunus persica (Pp.Cr) decreased the ulcer index in dose-dependent fashion as elaborated in Table 2. The value of ulcer index in intoxicated group was calculated as 4.5; whereas it was 1.5 in cimetidine treated group. The effects of Pp.Cr on ulcer indices in rats were found to be; 3.83, 2.99 and 2.16 at the doses of 100, 300 and 500 mg/kg respectively. The effects of Pp.Cr (500 mg/kg) on ulcer index were comparable with cimetidine treated group as depicted in Figure 3B.

Figure 3: graphs showing the effects of the crude extract Prunus persica (Pp.Cr) along with cimetidine (CIM), on (A) severity score, (B) Ulcer index and (C) percent protection in cysteamine-induced duodenal ulceration in rats.

lupinepublishers-openaccess-journal-gastroenterology-hepatology

Effects of Pp.Cr on Duodenal Percent Protection

Oral administration of Pp.Cr showed the protection against cysteamine-induced duodenal ulcer. The percentage protection observed at the dose of 100 mg/kg was 14.88%. The percentage protection was calculated as 33.55% at the dose of 300 mg/kg. Similarly, at the dose of 500 mg/kg percentage protection was found to be 52% as depicted in Figure 3C. The standard drug cimetidine showed significant antiulcer effects with percentage protection of 66.66% (Table 2). The antiulcerogenic potential of Pp.Cr at the dose of 500 mg/kg was comparable with that of standard control group.

Effects of Pp.Cr on Histopathological Parameters

No mucosal damage was observed in normal control group (Figure 4A). Intoxicated group showed inflammation and hemorrhagic spots in duodenal mucosa (Figure 4B). Histological examination indicated that pretreatment with different doses (100, 300 and 500 mg/kg) of crude extract of Pp.Cr and cimetidine (100mg/kg) showed the antiulcer effects as evidenced by reduction in inflammation and edema. Pretreatment with cimetidine showed the remarkable protection against cysteamine-induced duodenal ulcer (Figure 4F). Pp.Cr prevented the mucosal damage significantly (Figures 4C-4F).

Figure 4: The effects of different doses of Pp.Cr and cimetidine on cysteamine-induced histopathogical alterations (A) normal control, (B) intoxicated (cysteamine hydrochloride 600 mg/kg), (C) Pp.Cr 100 mg/kg + intoxication, (D) Pp.Cr 300mg/kg + intoxication, (E) Pp.Cr 500 mg/kg + intoxication and (F) CIM 100 mg/kg + intoxication.

lupinepublishers-openaccess-journal-gastroenterology-hepatology

Discussion

Ethanol has been reported to enhance the gastric acid secretion and reduce the blood flow, leading to microvascular injuries. It also causes the necrosis in the gastric mucosa, reducing the secretion of bicarbonates and gastric mucus [20]. Ethanol has also been found to induce mucosal cell surface damage and increases the permeability of mucosal capillaries, resulting in mucosal hemorrhage. These effects then allow the gastric acid back diffusion hence; exacerbate the mucosal damage already caused by ethanol [21]. So any substance that decreased the acid secretion or protects the mucosal layer could be gastroprotective. Standard drug, bismuth subsalicylate, showed the gastroprotective effects by forming a protective coating over gastric mucosa especially ulcerated sites to protect it from hydrolytic action of acid and pepsin. It also exerted the cytoprotective action by stimulating the prostaglandin biosynthesis, mucus and bicarbonate secretion [22]. The crude extract of Prunus persica (Pp.Cr) showed the presence of alkaloids, phenols and flavonoids. Alkaloids have been reported to possess the antiulcerogenic activity because of their ability to reduce gastric acid secretion, increase the pH of gastric contents and protect the mucous membrane [23]. Phenols have been reported to possess protective and therapeutic potential for peptic ulcer by up-regulating tissue growth factors and prostaglandins, down-regulating anti-angiogenic factors, enhancing endothelial nitric oxide synthase-derived NO, suppressing oxidative mucosal damage, amplifying antioxidant performance, antacid, and antisecretory activity and increasing endogenous mucosal defensive agents [24]. Flavonoids have been found to prevent the formation of free radicals and reduce injuries caused by oxidative stress [25]. Furthermore, Pp.Cr showed the presence of tannins which have been reported to produce layer over gut lining by precipitating micro proteins at ulcerative site, thus inhibit GIT secretions and also provide protection to gastrointestinal mucosa from irritants [26]. Tannins have also been found to resist the action of proteolytic enzymes produced by Helicobacter pylori [27].

Phytochemical analysis of Pp.Cr showed the presence of glycosides which have been found to reduce the expression of TNF-α [28]. Hence, the antiulcerative could be attributed to these secondary metabolites. H. pylori infection of the antral mucosa stimulates the release of gastrin by inhibiting the secretion of somatostatin. Gastrin has ability to enhance maximal acid secretory capacity. The administration of the crude extract of Prunus persica (Pp.Cr) was found to increase the pH of gastric contents, indicating that the extract could act as antisecretory agent because gastric acid back diffusion was one of major factors involved in the pathogenesis of ethanol- induced gastric ulcers. However, another possible mechanism of action could be its cytoprotective action; i.e. enhancement of the protective elements of the gastric mucosa; e.g. mucus and bicarbonate secretions in the same way as of bismuth subsalicylate, the standard drug. Exposure of gastric mucosa to necrotizing agents (e.g. ethanol) reduces these mucus and bicarbonate secretions, making gastric mucosa more susceptible to damaging action of gastric acid and pepsin. Ethanol also causes an increase in intracellular level of calcium, resulting in stimulation of gastric secretions [29]. The tannins present in the Pp.Cr could be the reason behind the decreased mucosal damage. The crude extract of Pp.Cr could also exert gastroprotective effects through cytoprotective action as ethanol has been reported to exert its direct toxic effects on gastric mucosa by reducing the secretion of bicarbonate ions and mucus. Ethanol has also been found to cause the gastric mucosal damage by producing free radicals leading to increased lipid peroxidation [30]. The P. persica plant extract could also have antioxidant potential that prevented the mucosal damage.

As peptic ulcer encompasses both gastric and duodenal ulcer, antiulcerogenic potential of the crude extract (Pp.Cr) was also assessed against cysteamine-induced duodenal ulcer alongwith ethanol-induced gastric ulcer. The cysteaime-induced duodenal ulcer model is a widely used and reproducible model of peptic ulcer because location, histopathology and pathophysiology of this chemically-induced ulcer are same as that of duodenal ulcer in humans [30]. Cysteamine has been studied to increase the gastrin level and thus increase the gastric acid secretory output. Cysteamine has also been reported to reduce the bicarbonate secretion and alkaline mucus secretion from the duodenal Brunner’s gland. Moreover, cysteamine-induced delayed gastric emptying causes the accumulation of gastric secretions in stomach. Due to the absence of peristaltic movement, these secretions do not mix with gastric contents. When these concentrated secretions enter the duodenum, where bicarbonate secretion is already reduced by cysteamine, they promote the ulcer formation [30]. The preventive effects of Pp.Cr in cysteaime-induced duodenal ulcer could be due to the presence of various secondary metabolites such as alkaloids, glycosides and tannins. The scavenging effects of flavonoids and phenols present in the Pp.Cr may also the reason of protective outcomes in duodenal ulcer. The histopathological studies of both stomach and duodenum further confirm the results.

Read More About Lupine Publishers Journal of Gastroenterology and Hepatology Please Click on Below Link:  https://currenttrendsingastroenterology.blogspot.com/

Tuesday, 12 October 2021

Lupine Publishers| Utilization of Direct Acting Oral Anticoagulants in Patients with Liver Cirrhosis: Is It Safe?

 Lupine Publishers| Journal of Gastroenterology and Hepatology


Abstract

Patients with liver cirrhosis are known to have increased risk bleeding particularly from gastrointestinal tract. However, recent literature has shown that patients with liver cirrhosis are also at increased risk of thrombotic complications. Therefore, it is important to consider anticoagulation in cirrhotic patients. The purpose of this article is to review the epidemiological studies available in scientific literature comparing the risk of bleeding in cirrhotic patients utilizing DOACs vs traditional anticoagulation.

Abbreviations: INR: International Normalized Ratio; VTE: Venous Thromboembolism; DVT: Deep Venous Thrombosis; PE: Pulmonary Embolism; PTT: Partial Thromboplastin Time; LMWH : Low-Molecular-Weight Heparin; NO: Nitric Oxide; PTT: Partial Thromboplastin Time; DOACs: Direct Oral Anticoagulants; AT: Antithrombin; ULN: Upper Limit Of Normal; AUC: Area Under The Plasma Concentration-Time Curve; PD pharmacodynamics; PK: pharmacokinetics

Introduction

Liver plays central physiologic role in hemostasis as it synthesizes the majority of the procoagulant and anticoagulant factors. The levels of these factors are markedly affected by decrease function of liver associated with cirrhosis resulting in abnormal hemostatic mechanism. Generally, the impression in the clinical world is that liver cirrhosis is associated with decrease synthesis of procoagulant factors resulting in increased risk of bleeding. This phenomenon is known as auto-anticoagulation and is supported by elevated international normalized ratio (INR) and low platelet count usually observed in cirrhotic patients. In this regard, gastrointestinal bleeding and more specifically variceal bleed is of major concern since they contribute significantly to the mortality of patients with liver cirrhosis. At least, 30% mortality has been reported at the first episode with a 70% recurrence rate in this patient population and a one year survival estimate ranging from 32% to 80% [1]. However, decrease function of cirrhotic liver also results in reduce level of anticoagulant factors including anti thrombin III, protein S, and C which may result in increased tendency to form clots. Interestingly, recent data also indicates cases of venous thromboembolism (VTE) including both deep venous thrombosis (DVT) and pulmonary embolism (PE) in cirrhotic patients ranging between 0.5% to 6.3% [2-10]. Dabbagh et al. [4] found that even an elevated INR > 2.2 was not protective against VTE in this patient population [4]. Gulley D et al. [10] noted that hospitalized cirrhotic patients without predisposing co-morbidities (e.g. neoplasm, congestive heart disease and chronic renal failure) had similar risks for VTE as compared to non cirrhotic patients [10]. Thus, the myth of auto-anticoagulation seems to be only partially true. Therefore, the abnormal routine blood tests (like elevated INR, Partial Thromboplastin Time [PTT], high MELD score and low platelet count) may indicate increased hemorrhage risk in this patient population which may not be completely protective against risk of VTE as these tests do not accurately reflect the activity of aforementioned anticoagulant factors in the serum. As a result, utilization of anticoagulation is now being increasingly encouraged in cirrhotic patient population to avoid thrombotic complications.

Direct oral anticoagulants (DOACs) are relatively newer class of anticoagulants which selectively inhibit factor Xa (for e.g. Apixaban, Rivaroxaban, and Edoxaban) and factor IIa (for e.g. Dabigatran) of the coagulation cascade. Being able to be administered orally, rapid onset of action, lack of heparin induced thrombocytopenia, fewer interactions, and non requirement of laboratory monitoring are some of the advantages that DOACs carry over the traditional anticoagulant agents. DOACs may also be helpful in management of portal vein thrombosis (PVT) and portal hypertension (pHTN) in patient with cirrhosis as case reports have been reported about PVT controlled by Rivaroxaban treatment [11-13]. Vilaseca M et al. [14] investigated the effect of Rivaroxaban on various mediators of portal hypertension in CCl4 and thio acetamide-cirrhotic rats. Rivaroxaban significantly decreased portal pressure in both models of cirrhosis by reducing oxidative stress, improving nitric oxide (NO) bioavailability, and ameliorating endothelial dysfunction. Rivaroxaban also markedly reduced intrahepatic microthrmbosis by reduced fibrin deposition and deactivated hepatic stellate cells which plays major role in increasing intrahepatic vascular resistance by promoting fibrogenesis [14]. The purpose of this article is to review the epidemiological studies available in scientific literature comparing the risk of bleeding in cirrhotic patients utilizing DOACs vs traditional anticoagulation.

Methods

An electronic Medline search was conducted using the key terms anticoagulation, oral anticoagulant, direct acting oral anticoagulant, novel oral anticoagulant, direct thrombin inhibitors, direct factor Xa inhibitors, Apixaban, Rivaroxaban, Dabigatran, Edoxaban, liver cirrhosis, chronic liver disease, and decompensated liver disease. Studies written in the English from January 2000 to March 2018 were considered for this review article. All search results were reviewed.

Results

Hum J et al. [15] conducted a retrospective cohort study to compare the efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in 45 patients with cirrhosis who were prescribed therapeutic anticoagulation over a 3-year period for thrombosis or prevention of stroke in patients with atrial fibrillation. 27 patients were prescribed one of the DOACs and 18 were prescribed vitamin K antagonist or low molecular weight heparin (LMWH). Similar total bleeding events (8 with DOACs vs 10 with other, P=0.12) were observed in the two groups but DOACs group had significantly less major bleeding events (1 [4%] vs 5 [28%], P = 0.03) [15]. In another retrospective study, Intagliata N et al. [16] compared the rates of bleeding in cirrhotic patients treated with DOACs (Rivaroxaban and Apixaban) to the cirrhotic patients treated with traditional anticoagulation (coumadin and LMWH) using a research database. The sample size consisted of 39 patients who received anticoagulation therapy over a 3-year period. 20 patients received DOACS and 19 received traditional anticoagulation. No significant difference in bleeding was observed in the two groups (three in the traditional anticoagulation group and four in the DOACS group, p = 0.9). Three major bleeding events were noted including two in the traditional anticoagulation group and one in the DOACS group [16]. Nagaoki Y et al. [17] also conducted a retrospective cohort study in fifty cirrhotic patients comparing the efficacy and safety of Edoxaban and warfarin for treatment of portal vein thrombosis (PVT). After treating for two weeks with danaparoid sodium, patients were switched to either Edoxaban (n = 20) or coumadin (n = 30). The efficacy and safety of Edoxaban and warfarin was compared for up to 6 months. Clinically significant gastrointestinal bleeding was encountered in 3 of 20 (15%) patients of the Edoxaban group and 2 of 30 (7%) of the warfarin group but the difference was not statistically significant (P = 0.335) [17]. In a relatively larger retrospective cohort study, Goriacko P et al. [18] compared the rate of bleeding in chronic liver disease patients with atrial fibrillation treated with oral anticoagulants (coumadin vs DOACs). No significant difference in all-cause bleeding (HR 0.9, 95% CI 0.4-1.8) and major bleeding were observed between the two groups [18].

Conclusion

The data on the safety of DOACs in patients with liver cirrhosis is in very initial stages. Based on our Medline literature search, we were able to find four studies comparing the risk of bleeding in cirrhotic patients utilizing DOACs vs traditional anticoagulation. All studies reported either decrease bleeding events in patients with liver disease treated with DOACs as compared to patients treated with traditional anticoagulation or no significant difference in bleeding risk. However, these studies were limited by retrospective nature, small sample size, and lack of randomization. Due to retrospective nature, underreporting of the bleeding events may have resulted in the underestimation of the risk of hemorrhage in these studies. Lack of randomization may have resulted in the underutilization of DOACs in cirrhotic patients at higher risk of bleeding such as those with high INR, low platelet count and presence of esophageal varices. This may have also confounded the results of these studies.

One of the major concerns regarding utilization of DOACs in cirrhotic patient population is the lack of specific antidotes in face of life-threatening gastrointestinal bleeding or urgent invasive procedure. Since DOACs have long half-life, drug discontinuation is insufficient in these circumstances. Recently, three agents including Idarucizumab, andexanet alfa, and ciraparantag have been introduced with promising antidotal effect against the DOACs [19]. Idarucizumab is the only agent to date which has been approved for use and is specific to Dabigatran [19]. Andexanet alfa is specific to factor Xa inhibitors and is still under investigation [19]. Ciraparantag is a universal antidote and is in earlier stages of development [19]. In a study on healthy volunteers, Prothrmobin complex concentrate has been demonstrated to reverse the anticoagulant effect of Rivaroxaban and Dabigatran [20]. In another study, prothrombin concentrates and recombinant factor VIIA were added in vitro to plasma from healthy volunteers receiving Rivaroxaban and Dabigatran with (partial) reversal of these agents [21].

Another concern regarding the utilization of DOACs in patients with liver disease is that the abnormal functioning of liver may affect the pharmacodynamics (PD) and pharmacokinetics (PK) of DOACs resulting in altered half-life and serum concentration of these agents in this patient population. As a result, caution and dose adjustment may be required when using DOACs in patients with abnormal liver function. Graff J et al. [22] observed that in patients with moderately impaired liver function (i.e. Child-Pugh classification B), the area under the plasma concentration-time curve (AUC) of Rivaroxaban after a single dose of 10 mg increased by 2.27-fold along with increase in factor Xa inhibition [22]. Since, Rivaroxaban is also excreted mainly by the kidneys (66%) and liver (34%), caution and dose adjustment of this agent is recommended in cirrhotic patients with cirrhosis with or without concomitant renal failure [22]. Rivaroxaban is also contraindicated in patients with liver cirrhosis associated with coagulopathy, increased bleeding risk, and patients classified as Child-Pugh B and C [22]. In contrast, the AUC of Dabigatran after a single dose of 150 mg decreased by 5.6 % in patients with moderately impaired liver function (i.e. Child-Pugh classification B) [22]. Also, Dabigatran is mainly (80%) eliminated via the kidneys and is likely the more safer choice in patients with liver cirrhosis [23]. Stangier J et al. [23] observed slower conversion of Dabigatran intermediate to active Dabigatran [24]. However, total drug exposure was comparable between healthy volunteers (n = 12) and patients with hepatic impairment (Child Pugh classification B, n = 12) [24]. Moreover, the parameters of coagulation, including activated partial thrmboplastin time, clotting time, and thrombin time relationships were basically similar in both groups [24]. Therefore, Dabigatran can be used in patients with moderate hepatic impairment without the need for dose adjustment [24]. Dabigatran should be avoided in patients with elevated hepatic enzymes (>2× ULN) and is contraindicated in patients with hepatic impairment expected to have any impact on survival [22]. Increased AUC by 1.09-fold was observed for Apixaban after a single dose administration of 5 mg whereas AUC of Edoxaban decreased by 5.6 % after single dose administration of 15 mg [22]. In patients with mild (Child-Pugh A) or moderate (Child- Pugh B) hepatic dysfunction or transaminase levels >2× upper limit of normal (ULN), Apixaban can be used with caution. Apixaban should be avoided in patients with severe hepatic impairment and in those with hepatic impairment with increased bleeding risk [22].

It will be helpful to monitor activity of DOACs in cirrhotic patients particularly at increased risk of bleeding for example patients with esophageal varices, elevated INR, and low platelet count. Novel coagulation assays need to be developed to monitor the activity of DOACs in serum from patients with liver disease. In one study, Potze W et al. [25] noticed substantial reduction in anti- Xa levels when antithrombin (AT) dependent anticoagulant drugs (Unfractioned heparin, LMWH, and fondaparinux) were added to the plasma of patients with cirrhosis as compared to plasma from healthy controls. Therefore, they concluded that anti-Xa assay cannot be used to monitor AT-dependent anticoagulant drugs in patients with cirrhosis, as it may result in underestimation of drug levels and increase risk of bleeding. However, this was not the case with Rivaroxaban and Dabigatran and they recommended that direct factor Xa and IIa inhibitors may be monitored through the respective anti-Xa and anti-IIa assays in patients with cirrhosis.

Read More About  Lupine Publishers Journal of Gastroenterology and Hepatology Please Click on Below Link: https://currenttrendsingastroenterology.blogspot.com

Tuesday, 7 September 2021

Lupine Publishers| Utilization of Direct Acting Oral Anticoagulants in Patients with Liver Cirrhosis: Is It Safe?

 Lupine Publishers| Current Trends in Gastroenterology and Hepatology


Abstract

Patients with liver cirrhosis are known to have increased risk bleeding particularly from gastrointestinal tract. However, recent literature has shown that patients with liver cirrhosis are also at increased risk of thrombotic complications. Therefore, it is important to consider anticoagulation in cirrhotic patients. The purpose of this article is to review the epidemiological studies available in scientific literature comparing the risk of bleeding in cirrhotic patients utilizing DOACs vs traditional anticoagulation.

Abbreviations: INR: International Normalized Ratio; VTE: Venous Thromboembolism; DVT: Deep Venous Thrombosis; PE: Pulmonary Embolism; PTT: Partial Thromboplastin Time; LMWH : Low-Molecular-Weight Heparin; NO: Nitric Oxide; PTT: Partial Thromboplastin Time; DOACs: Direct Oral Anticoagulants; AT: Antithrombin; ULN: Upper Limit Of Normal; AUC: Area Under The Plasma Concentration-Time Curve; PD pharmacodynamics; PK: pharmacokinetics

Introduction

Liver plays central physiologic role in hemostasis as it synthesizes the majority of the procoagulant and anticoagulant factors. The levels of these factors are markedly affected by decrease function of liver associated with cirrhosis resulting in abnormal hemostatic mechanism. Generally, the impression in the clinical world is that liver cirrhosis is associated with decrease synthesis of procoagulant factors resulting in increased risk of bleeding. This phenomenon is known as auto-anticoagulation and is supported by elevated international normalized ratio (INR) and low platelet count usually observed in cirrhotic patients. In this regard, gastrointestinal bleeding and more specifically variceal bleed is of major concern since they contribute significantly to the mortality of patients with liver cirrhosis. At least, 30% mortality has been reported at the first episode with a 70% recurrence rate in this patient population and a one year survival estimate ranging from 32% to 80% [1]. However, decrease function of cirrhotic liver also results in reduce level of anticoagulant factors including anti thrombin III, protein S, and C which may result in increased tendency to form clots. Interestingly, recent data also indicates cases of venous thromboembolism (VTE) including both deep venous thrombosis (DVT) and pulmonary embolism (PE) in cirrhotic patients ranging between 0.5% to 6.3% [2-10]. Dabbagh et al. [4] found that even an elevated INR > 2.2 was not protective against VTE in this patient population [4]. Gulley D et al. [10] noted that hospitalized cirrhotic patients without predisposing co-morbidities (e.g. neoplasm, congestive heart disease and chronic renal failure) had similar risks for VTE as compared to non cirrhotic patients [10]. Thus, the myth of auto-anticoagulation seems to be only partially true. Therefore, the abnormal routine blood tests (like elevated INR, Partial Thromboplastin Time [PTT], high MELD score and low platelet count) may indicate increased hemorrhage risk in this patient population which may not be completely protective against risk of VTE as these tests do not accurately reflect the activity of aforementioned anticoagulant factors in the serum. As a result, utilization of anticoagulation is now being increasingly encouraged in cirrhotic patient population to avoid thrombotic complications.

Direct oral anticoagulants (DOACs) are relatively newer class of anticoagulants which selectively inhibit factor Xa (for e.g. Apixaban, Rivaroxaban, and Edoxaban) and factor IIa (for e.g. Dabigatran) of the coagulation cascade. Being able to be administered orally, rapid onset of action, lack of heparin induced thrombocytopenia, fewer interactions, and non requirement of laboratory monitoring are some of the advantages that DOACs carry over the traditional anticoagulant agents. DOACs may also be helpful in management of portal vein thrombosis (PVT) and portal hypertension (pHTN) in patient with cirrhosis as case reports have been reported about PVT controlled by Rivaroxaban treatment [11-13]. Vilaseca M et al. [14] investigated the effect of Rivaroxaban on various mediators of portal hypertension in CCl4 and thio acetamide-cirrhotic rats. Rivaroxaban significantly decreased portal pressure in both models of cirrhosis by reducing oxidative stress, improving nitric oxide (NO) bioavailability, and ameliorating endothelial dysfunction. Rivaroxaban also markedly reduced intrahepatic microthrmbosis by reduced fibrin deposition and deactivated hepatic stellate cells which plays major role in increasing intrahepatic vascular resistance by promoting fibrogenesis [14]. The purpose of this article is to review the epidemiological studies available in scientific literature comparing the risk of bleeding in cirrhotic patients utilizing DOACs vs traditional anticoagulation.

Methods

An electronic Medline search was conducted using the key terms anticoagulation, oral anticoagulant, direct acting oral anticoagulant, novel oral anticoagulant, direct thrombin inhibitors, direct factor Xa inhibitors, Apixaban, Rivaroxaban, Dabigatran, Edoxaban, liver cirrhosis, chronic liver disease, and decompensated liver disease. Studies written in the English from January 2000 to March 2018 were considered for this review article. All search results were reviewed.

Results

Hum J et al. [15] conducted a retrospective cohort study to compare the efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in 45 patients with cirrhosis who were prescribed therapeutic anticoagulation over a 3-year period for thrombosis or prevention of stroke in patients with atrial fibrillation. 27 patients were prescribed one of the DOACs and 18 were prescribed vitamin K antagonist or low molecular weight heparin (LMWH). Similar total bleeding events (8 with DOACs vs 10 with other, P=0.12) were observed in the two groups but DOACs group had significantly less major bleeding events (1 [4%] vs 5 [28%], P = 0.03) [15]. In another retrospective study, Intagliata N et al. [16] compared the rates of bleeding in cirrhotic patients treated with DOACs (Rivaroxaban and Apixaban) to the cirrhotic patients treated with traditional anticoagulation (coumadin and LMWH) using a research database. The sample size consisted of 39 patients who received anticoagulation therapy over a 3-year period. 20 patients received DOACS and 19 received traditional anticoagulation. No significant difference in bleeding was observed in the two groups (three in the traditional anticoagulation group and four in the DOACS group, p = 0.9). Three major bleeding events were noted including two in the traditional anticoagulation group and one in the DOACS group [16]. Nagaoki Y et al. [17] also conducted a retrospective cohort study in fifty cirrhotic patients comparing the efficacy and safety of Edoxaban and warfarin for treatment of portal vein thrombosis (PVT). After treating for two weeks with danaparoid sodium, patients were switched to either Edoxaban (n = 20) or coumadin (n = 30). The efficacy and safety of Edoxaban and warfarin was compared for up to 6 months. Clinically significant gastrointestinal bleeding was encountered in 3 of 20 (15%) patients of the Edoxaban group and 2 of 30 (7%) of the warfarin group but the difference was not statistically significant (P = 0.335) [17]. In a relatively larger retrospective cohort study, Goriacko P et al. [18] compared the rate of bleeding in chronic liver disease patients with atrial fibrillation treated with oral anticoagulants (coumadin vs DOACs). No significant difference in all-cause bleeding (HR 0.9, 95% CI 0.4-1.8) and major bleeding were observed between the two groups [18].

Conclusion

The data on the safety of DOACs in patients with liver cirrhosis is in very initial stages. Based on our Medline literature search, we were able to find four studies comparing the risk of bleeding in cirrhotic patients utilizing DOACs vs traditional anticoagulation. All studies reported either decrease bleeding events in patients with liver disease treated with DOACs as compared to patients treated with traditional anticoagulation or no significant difference in bleeding risk. However, these studies were limited by retrospective nature, small sample size, and lack of randomization. Due to retrospective nature, underreporting of the bleeding events may have resulted in the underestimation of the risk of hemorrhage in these studies. Lack of randomization may have resulted in the underutilization of DOACs in cirrhotic patients at higher risk of bleeding such as those with high INR, low platelet count and presence of esophageal varices. This may have also confounded the results of these studies.

One of the major concerns regarding utilization of DOACs in cirrhotic patient population is the lack of specific antidotes in face of life-threatening gastrointestinal bleeding or urgent invasive procedure. Since DOACs have long half-life, drug discontinuation is insufficient in these circumstances. Recently, three agents including Idarucizumab, andexanet alfa, and ciraparantag have been introduced with promising antidotal effect against the DOACs [19]. Idarucizumab is the only agent to date which has been approved for use and is specific to Dabigatran [19]. Andexanet alfa is specific to factor Xa inhibitors and is still under investigation [19]. Ciraparantag is a universal antidote and is in earlier stages of development [19]. In a study on healthy volunteers, Prothrmobin complex concentrate has been demonstrated to reverse the anticoagulant effect of Rivaroxaban and Dabigatran [20]. In another study, prothrombin concentrates and recombinant factor VIIA were added in vitro to plasma from healthy volunteers receiving Rivaroxaban and Dabigatran with (partial) reversal of these agents [21].

Another concern regarding the utilization of DOACs in patients with liver disease is that the abnormal functioning of liver may affect the pharmacodynamics (PD) and pharmacokinetics (PK) of DOACs resulting in altered half-life and serum concentration of these agents in this patient population. As a result, caution and dose adjustment may be required when using DOACs in patients with abnormal liver function. Graff J et al. [22] observed that in patients with moderately impaired liver function (i.e. Child-Pugh classification B), the area under the plasma concentration-time curve (AUC) of Rivaroxaban after a single dose of 10 mg increased by 2.27-fold along with increase in factor Xa inhibition [22]. Since, Rivaroxaban is also excreted mainly by the kidneys (66%) and liver (34%), caution and dose adjustment of this agent is recommended in cirrhotic patients with cirrhosis with or without concomitant renal failure [22]. Rivaroxaban is also contraindicated in patients with liver cirrhosis associated with coagulopathy, increased bleeding risk, and patients classified as Child-Pugh B and C [22]. In contrast, the AUC of Dabigatran after a single dose of 150 mg decreased by 5.6 % in patients with moderately impaired liver function (i.e. Child-Pugh classification B) [22]. Also, Dabigatran is mainly (80%) eliminated via the kidneys and is likely the more safer choice in patients with liver cirrhosis [23]. Stangier J et al. [23] observed slower conversion of Dabigatran intermediate to active Dabigatran [24]. However, total drug exposure was comparable between healthy volunteers (n = 12) and patients with hepatic impairment (Child Pugh classification B, n = 12) [24]. Moreover, the parameters of coagulation, including activated partial thrmboplastin time, clotting time, and thrombin time relationships were basically similar in both groups [24]. Therefore, Dabigatran can be used in patients with moderate hepatic impairment without the need for dose adjustment [24]. Dabigatran should be avoided in patients with elevated hepatic enzymes (>2× ULN) and is contraindicated in patients with hepatic impairment expected to have any impact on survival [22]. Increased AUC by 1.09-fold was observed for Apixaban after a single dose administration of 5 mg whereas AUC of Edoxaban decreased by 5.6 % after single dose administration of 15 mg [22]. In patients with mild (Child-Pugh A) or moderate (Child- Pugh B) hepatic dysfunction or transaminase levels >2× upper limit of normal (ULN), Apixaban can be used with caution. Apixaban should be avoided in patients with severe hepatic impairment and in those with hepatic impairment with increased bleeding risk [22].

It will be helpful to monitor activity of DOACs in cirrhotic patients particularly at increased risk of bleeding for example patients with esophageal varices, elevated INR, and low platelet count. Novel coagulation assays need to be developed to monitor the activity of DOACs in serum from patients with liver disease. In one study, Potze W et al. [25] noticed substantial reduction in anti- Xa levels when antithrombin (AT) dependent anticoagulant drugs (Unfractioned heparin, LMWH, and fondaparinux) were added to the plasma of patients with cirrhosis as compared to plasma from healthy controls. Therefore, they concluded that anti-Xa assay cannot be used to monitor AT-dependent anticoagulant drugs in patients with cirrhosis, as it may result in underestimation of drug levels and increase risk of bleeding. However, this was not the case with Rivaroxaban and Dabigatran and they recommended that direct factor Xa and IIa inhibitors may be monitored through the respective anti-Xa and anti-IIa assays in patients with cirrhosis.

Read More About Lupine Publishers Current Trends in Gastroenterology and Hepatology Please Click on Below Link: https://currenttrendsingastroenterology.blogspot.com/